Oncimmune Holdings PLC Director/PDMR Shareholding (8353U)
October 27 2017 - 4:32AM
UK Regulatory
TIDMONC
RNS Number : 8353U
Oncimmune Holdings PLC
27 October 2017
27 October 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND
PERSONS CLOSELY ASSOCIATED WITH THEM
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, today announces that on 25 October
2017, share options over 420,000 GBP0.01 ordinary shares of the
Company were awarded to staff and directors (who are PDMRs) under
the Company's 2016 Share Option Plan (an amalgamation of the
Company's 2005 and 2007 Share Option Plans) as follows.
Name Position Number of Exercise price Percentage of
Share Options per Share issued ordinary
Awarded share capital
----------------- ----------------- --------------- --------------- -----------------
Meinhard Non-executive
Schmidt Chairman 300,000 GBP1.215 0.552%
----------------- ----------------- --------------- --------------- -----------------
Chief Financial
Andrew Millet Officer 30,000 GBP1.215 0.055%
----------------- ----------------- --------------- --------------- -----------------
Other employees
(not directors
or PDMR's) 90,000 GBP1.215 0.165%
------------------------------------ --------------- --------------- -----------------
The options are subject to the rules of the 2016 Share Option
Plan and vest in five equal annual parts, the first fifth vesting
on 27 October 2018 and each year thereafter for a further four
years, subject to continued employment. Unless otherwise indicated
in the table above, the options are exercisable at 121.5 pence,
being the mid-market price of the Company's ordinary shares at the
close of day on 25 October 2017
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Meinhard Schmidt
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
Non-Executive Chairman, Director
a) Position/status
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI 213800HCYIWT6YPI1I02
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of options over 1p ordinary shares - 2016 Share Option
instrument Plan
Identification code
ISIN GB00BYQ94H38
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of options over ordinary shares
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 300,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 25 October 2016
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction N/A
---- ------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Andrew Millet
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
Chief Financial Officer, Director
a) Position/status
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Oncimmune Holdings Plc
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI 213800HCYIWT6YPI1I02
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of options over 1p ordinary shares - 2016 Share Option
instrument Plan
Identification code ISIN GB00BYQ94H38
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of options over ordinary shares
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
N/A 30,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information Price(s) Volume(s)
---------- ----------
N/A 30,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 25 October 2017
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction N/A
---- ------------------------------------------------------- -------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGCBDGGXDBGRR
(END) Dow Jones Newswires
October 27, 2017 05:32 ET (09:32 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024